Market Cap 2.36B
Revenue (ttm) 0.00
Net Income (ttm) -36.14M
EPS (ttm) N/A
PE Ratio 0.00
Forward PE N/A
Profit Margin 0.00%
Debt to Equity Ratio 0.00
Volume 70,100
Avg Vol 47,788
Day's Range N/A - N/A
Shares Out 31.84M
Stochastic %K 100%
Beta -1.46
Analysts Strong Sell
Price Target $93.25

Company Profile

Belite Bio, Inc, a clinical stage biopharmaceutical drug development company, engages in the research and development of novel therapeutics targeting retinal degenerative eye diseases with unmet medical needs in the United States. Its lead product candidate is Tinlarebant (LBS-008), an orally administered, which is in phase 3 clinical trial as an early intervention for maintaining the health and integrity of retinal tissues in stargardt disease type 1 and geographic atrophy patients. The company...

Industry: Biotechnology
Sector: Healthcare
Phone: 858 246 6240
Address:
12750 High Bluff Drive, Suite 475, San Diego, United States
Doozio
Doozio Oct. 4 at 8:48 PM
$BLTE out of the tightness it’s faatch 💣 or….
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 10:03 AM
$BLTE Outstanding article that hits the mark on BLTE's current state. So if you want to refresh your BLTE insights or learn about BLTE from scratch, this is a must read. https://beyondspx.com/quote/BLTE/analysis/belite-bio-unlocking-retinal-health-with-a-novel-oral-approach-nasdaq-blte
1 · Reply
SilverEagle
SilverEagle Oct. 2 at 6:22 PM
$BLTE looks ripe for a hulk candle
0 · Reply
Doozio
Doozio Sep. 26 at 12:49 PM
$BLTE it was always 🐒🍌🧠⏰♾️ but yo need them huckleberries back for Roger to get into that gap $EXEL again n $SEZL them 🐑 TTWO get NUTX
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 10:02 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $BLTE $SOC $LYFT $UBER $AMSC l
0 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 12:00 PM
HC Wainwright & Co. has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Buy with a target price of 100 → 98.
0 · Reply
jlsnet22
jlsnet22 Sep. 12 at 12:54 PM
$BLTE https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-completion-dragon-2-year-phase-3-trial-oral/
0 · Reply
DonCorleone77
DonCorleone77 Sep. 8 at 12:33 PM
$BLTE Belite Bio announces up to $250M upsized private placement financing
0 · Reply
waterlock
waterlock Sep. 4 at 2:02 AM
$BLTE Does any know what fellow eyes represents in their DRAGON study? I checked their clinical trial info, doesn’t see anything saying fellow eyes specifically. I assume it is the placebo group. But, In their interim trial, BCVA shows that treated eyes has (almost) the same results as fellow eyes. I kinda assumed that the treated eyes should have BETTER corrected vision and not just the same? I assumed fellow eyes should have deteriorated BCVA. Can someone help here?
2 · Reply
ChartCortex
ChartCortex Aug. 23 at 7:40 AM
$BLTE Belite Bio Inc is a clinical stage ophthalmology company with regulatory milestones ahead
0 · Reply
Latest News on BLTE
Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript

Aug 11, 2025, 11:36 PM EDT - 7 weeks ago

Belite Bio, Inc (BLTE) Q2 2025 Earnings Call Transcript


Belite Bio Announces Registered Direct Offering of $15 Million

Aug 7, 2025, 8:00 AM EDT - 2 months ago

Belite Bio Announces Registered Direct Offering of $15 Million


Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript

May 15, 2025, 4:59 AM EDT - 5 months ago

Belite Bio, Inc (BLTE) Q1 2025 Earnings Call Transcript


Belite Bio to Participate in Four Upcoming Investor Conferences

May 12, 2025, 8:00 AM EDT - 5 months ago

Belite Bio to Participate in Four Upcoming Investor Conferences


Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript

Mar 17, 2025, 6:40 PM EDT - 7 months ago

Belite Bio, Inc. (BLTE) Q4 2024 Earnings Call Transcript


Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript

Nov 12, 2024, 8:28 PM EST - 11 months ago

Belite Bio, Inc. (BLTE) Q3 2024 Earnings Call Transcript


Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript

Aug 12, 2024, 10:35 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q2 2024 Earnings Call Transcript


Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript

May 14, 2024, 8:11 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q1 2024 Earnings Call Transcript


Belite Bio Announces $25 Million Registered Direct Offering

Apr 25, 2024, 7:15 PM EDT - 1 year ago

Belite Bio Announces $25 Million Registered Direct Offering


Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript

Mar 12, 2024, 7:53 PM EDT - 1 year ago

Belite Bio, Inc (BLTE) Q4 2023 Earnings Call Transcript


Belite Bio to Participate in the BTIG Ophthalmology Day

Nov 20, 2023, 8:00 AM EST - 2 years ago

Belite Bio to Participate in the BTIG Ophthalmology Day


Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript

Nov 14, 2023, 11:30 PM EST - 2 years ago

Belite Bio, Inc (BLTE) Q3 2023 Earnings Call Transcript


Doozio
Doozio Oct. 4 at 8:48 PM
$BLTE out of the tightness it’s faatch 💣 or….
0 · Reply
NVDAMillionaire
NVDAMillionaire Oct. 3 at 10:03 AM
$BLTE Outstanding article that hits the mark on BLTE's current state. So if you want to refresh your BLTE insights or learn about BLTE from scratch, this is a must read. https://beyondspx.com/quote/BLTE/analysis/belite-bio-unlocking-retinal-health-with-a-novel-oral-approach-nasdaq-blte
1 · Reply
SilverEagle
SilverEagle Oct. 2 at 6:22 PM
$BLTE looks ripe for a hulk candle
0 · Reply
Doozio
Doozio Sep. 26 at 12:49 PM
$BLTE it was always 🐒🍌🧠⏰♾️ but yo need them huckleberries back for Roger to get into that gap $EXEL again n $SEZL them 🐑 TTWO get NUTX
0 · Reply
GMExAPE
GMExAPE Sep. 17 at 10:02 PM
RMFC stock has 5X potential, shorts at zero borrow and the 3m float is locked. Very undervalued here. Historic short squeeze coming - No dilution - Catalysts coming - Just reported record financials and added a new store a few weeks ago. $BLTE $SOC $LYFT $UBER $AMSC l
0 · Reply
JarvisFlow
JarvisFlow Sep. 15 at 12:00 PM
HC Wainwright & Co. has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Buy with a target price of 100 → 98.
0 · Reply
jlsnet22
jlsnet22 Sep. 12 at 12:54 PM
$BLTE https://investors.belitebio.com/news-releases/news-release-details/belite-bio-announces-completion-dragon-2-year-phase-3-trial-oral/
0 · Reply
DonCorleone77
DonCorleone77 Sep. 8 at 12:33 PM
$BLTE Belite Bio announces up to $250M upsized private placement financing
0 · Reply
waterlock
waterlock Sep. 4 at 2:02 AM
$BLTE Does any know what fellow eyes represents in their DRAGON study? I checked their clinical trial info, doesn’t see anything saying fellow eyes specifically. I assume it is the placebo group. But, In their interim trial, BCVA shows that treated eyes has (almost) the same results as fellow eyes. I kinda assumed that the treated eyes should have BETTER corrected vision and not just the same? I assumed fellow eyes should have deteriorated BCVA. Can someone help here?
2 · Reply
ChartCortex
ChartCortex Aug. 23 at 7:40 AM
$BLTE Belite Bio Inc is a clinical stage ophthalmology company with regulatory milestones ahead
0 · Reply
JarvisFlow
JarvisFlow Jul. 3 at 11:30 AM
HC Wainwright & Co. has updated their rating for Belite Bio ( $BLTE ) to Buy with a price target of 100.
0 · Reply
DonCorleone77
DonCorleone77 Jul. 2 at 9:58 AM
$BLTE Belite Bio completes enrollment in PHOENIX trial Belite Bio announced the completion of enrollment in the PHOENIX trial, a global, 24-month Phase 3 pivotal trial evaluating the safety and tolerability of Tinlarebant and its potential to reduce atrophic lesion growth rate in patients diagnosed with geographic atrophy in dry age-related macular degeneration.
0 · Reply
waterlock
waterlock Jun. 25 at 1:59 AM
$BLTE bad news for BLTE https://www.fiercebiotech.com/biotech/sanofi-backed-splicebio-secures-135m-series-b-eye-disease-gene-therapy-trials
1 · Reply
swingingtech
swingingtech Jun. 6 at 9:37 PM
$BLTE https://wallstreetwaves.com/blte-experiences-significant-drop-below-essential-moving-average/
0 · Reply
justiceforb_85
justiceforb_85 Jun. 6 at 7:50 PM
$BLTE adding on this dip.
0 · Reply
justiceforb_85
justiceforb_85 May. 22 at 3:44 AM
$BLTE tinlarebant promising in Stargardt disease. However, appears P3 trial is in Japanese patients which will raise a significant concern with FDA. Are there any studies being conducted in US patients?
1 · Reply
MaverikIT
MaverikIT May. 21 at 2:36 PM
@IsabellaDC $GPUS $WRD $BLTE
0 · Reply
SilverEagle
SilverEagle May. 21 at 1:36 PM
$BLTE watching 👀 👀
0 · Reply
waterlock
waterlock May. 21 at 10:52 AM
$BLTE ?? BTD now? That sounds weird. Usually at much earlier time. At Phase 3?
0 · Reply
Thestocktraderhubzee
Thestocktraderhubzee May. 21 at 9:56 AM
WATCHLIST MAY 21 2025 $BLTE Belite Bio Secures FDA Breakthrough Therapy Designation For Tinlarebant In Stargardt Disease Following Phase 3 Interim Data $JNJ Reported Earlier, J&J's DARZALEX FASPRO Wins US FDA Oncologic Drugs Advisory Committee Backing For Early Intervention In HR-SMM, Potentially Preventing Disease Progression $PLTR Palantir Partners With SAP To Fuse Ontology, Foundry And Enterprise Data: CEO Alex Karp Calls It 'Extremely Valuable' $WRD WeRide Reveals Plan To Boost Commercial Robotaxi Services To 15 Additional Cities Globally $HD Home Depot Accelerates Supply Chain Diversification, Shifts Sourcing Away From Single Countries: Management Sees 'Limited Impact' From Tariffs
0 · Reply
SilverEagle
SilverEagle May. 15 at 4:38 PM
$BLTE > 70 + volume may be special.
0 · Reply
JarvisFlow
JarvisFlow May. 15 at 3:24 PM
Cantor Fitzgerald has adjusted their stance on Belite Bio ( $BLTE ), setting the rating to Overweight.
0 · Reply